BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med 1999;107:77S-85S. [PMID: 10451013 DOI: 10.1016/s0002-9343(99)00104-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Rocha P, Baleeiro C, Tunkel AR. Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections. Curr Infect Dis Rep 2000;2:399-408. [PMID: 11095884 DOI: 10.1007/s11908-000-0066-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
2 Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:3261-4. [PMID: 12234855 DOI: 10.1128/AAC.46.10.3261-3264.2002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
3 Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004;48:3954-8. [PMID: 15388458 DOI: 10.1128/AAC.48.10.3954-3958.2004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
4 Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867-74. [PMID: 12760860 DOI: 10.1128/AAC.47.6.1867-1874.2003] [Cited by in Crossref: 122] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]